MLH1 and cancer: There are many gaps in knowledge regarding surveillance, particularly given the high rate of interval cancers detected (i.e., in MLH1-mutant LS) and the lack of evidence regarding the clinical effectiveness of cancer screening for extra-colonic LS cancers.